https://www.oncohost.com https://www.oncohost.com/contact https://www.oncohost.com/for-pharma https://www.oncohost.com/for-patients https://www.oncohost.com/for-providers https://www.oncohost.com/about https://www.oncohost.com/product-technology https://www.oncohost.com/product-nsclc https://www.oncohost.com/science https://www.oncohost.com/careers https://www.oncohost.com/portal-registration https://www.oncohost.com/news https://www.oncohost.com/privacy-policy https://www.oncohost.com/terms-of-use https://www.oncohost.com/order-a-test https://www.oncohost.com/cookie-policy https://www.oncohost.com/order/thank-you https://www.oncohost.com/thank-you https://www.oncohost.com/ourpublications https://www.oncohost.com/nsclc/thank-you https://www.oncohost.com/for-phlebotomists https://www.oncohost.com/news/2022-predictions-for-ai-and-machine-learning-in-healthcare https://www.oncohost.com/news/3-israeli-companies-win-2025-big-innovation-awards https://www.oncohost.com/news/3-researchers-developing-innovative-strategies-in-cancer-therapy https://www.oncohost.com/news/35-million-in-new-funding-for-ai-to-personalize-cancer-treatment https://www.oncohost.com/news/8m-in-bird-grants-go-to-israeli-us-collaborations-in-agtech-and-health https://www.oncohost.com/news/addressing-one-of-the-most-common-dilemmas-faced-by-oncologists https://www.oncohost.com/news/ai-big-data-a-bright-new-diagnosis-roundtable https://www.oncohost.com/news/ai-ml-enables-earlier-cancer-detection-guided-treatment https://www.oncohost.com/news/ai-powered-oncology-platform-raises-35-million-series-c-funding-round https://www.oncohost.com/news/ai-tool-helps-doctors-pick-optimum-cancer-treatment-for-patients https://www.oncohost.com/news/appointments-and-advancements-for-november-13-2024 https://www.oncohost.com/news/appointments-and-advancements-for-oct-3-2022 https://www.oncohost.com/news/as-ai-dawns-in-precision-oncology-2025-expected-to-be-a-turning-point https://www.oncohost.com/news/at-biomed-israel-conference-medical-start-ups-discuss-challenges-in-reaching-success https://www.oncohost.com/news/back-to-the-future-developments-in-immunotherapy-with-david-gandara-md https://www.oncohost.com/news/backed-by-eu-funds-israeli-researcher-tackles-treatment-resistant-cancer https://www.oncohost.com/news/be-human-founders-reveal-how-to-secure-real-investment-for-your-startup https://www.oncohost.com/news/beyond-biotech-podcast-32-cancer-research-horizons-enterome-oncohost-trakcel-turbine https://www.oncohost.com/news/bio-food-precision-oncology-to-take-center-stage-at-biomed-summit-in-tel-aviv https://www.oncohost.com/news/biomed-2024-showcases-israels-resilient-entrepreneurial-spirit https://www.oncohost.com/news/biotech-in-a-time-of-war https://www.oncohost.com/news/blood-test-offers-hope-for-lung-cancer-patients https://www.oncohost.com/news/by-next-year-will-doctors-finally-have-the-technology-to-fully-personalize-treatments-for-lung-cancer-patients https://www.oncohost.com/news/can-oncohosts-prophet-predict-host-response-to-cancer-treatments-investors-are-waiting-to-find-out https://www.oncohost.com/news/clinical-lung-cancer-publishes-study-93-of-oncologists-adjust-treatment-recommendations-with-oncohosts-prophetnsclc-test https://www.oncohost.com/news/clinical-study-identifies-personalized-treatment-options-for-metastatic-non-small-cell-lung-cancer-with-plasma-proteome-testing https://www.oncohost.com/news/companies-partner-to-identify-biomarkers-for-renal-cell-carcinoma https://www.oncohost.com/news/ctechs-20-minute-leaders-podcast-interview-with-ofer-sharon-ceo-of-oncohost https://www.oncohost.com/news/dana-farber-cancer-institute-and-oncohost-partner-for-renal-cell-carcinoma-research https://www.oncohost.com/news/decibios-peripheral-biomarkers-q-a-with-dr-ofer-sharon-of-oncohost https://www.oncohost.com/news/developing-personalized-strategies-to-maximize-cancer-therapy-success https://www.oncohost.com/news/digital-health-news-funding-roundup-in-the-prior-week-may-16-2022 https://www.oncohost.com/news/dr-ofer-sharon-ceo-of-oncohost-discusses-technology-to-improve-cancer-care https://www.oncohost.com/news/dr-ofer-sharon-ceo-of-oncohost-interview-series https://www.oncohost.com/news/dr-ofer-sharon-ceo-of-oncohost-talks-the-potential-impact-of-precision-medicine-on-cancer-therapy https://www.oncohost.com/news/driving-progress-in-personalized-cancer-therapy https://www.oncohost.com/news/editors-and-readers-choice-10-favorite-nocamels-articles https://www.oncohost.com/news/first-of-its-kind-lab-to-improve-personalized-cancer-therapy-opens-in-israel https://www.oncohost.com/news/first-of-its-kind-lab-to-improve-personalized-cancer-therapy-opens-in-israel-2 https://www.oncohost.com/news/florida-cancer-specialists-research-institute-participating-in-global-clinical-trial-analyzing-patient-responsiveness-to-immunotherapy-treatment https://www.oncohost.com/news/fortune-term-sheet-newsletter https://www.oncohost.com/news/global-roundup-aussie-biopharma-raises-25-million-to-expand-in-us https://www.oncohost.com/news/global-roundup-medtronic-kicks-off-aortic-stenosis-study-in-japan https://www.oncohost.com/news/global-roundup-olink-publishes-updated-genetic-atlas-of-the-plasma-proteome https://www.oncohost.com/news/harnessing-precision-medicine-oncology-ofer-sharon-md https://www.oncohost.com/news/health-it-appointments-and-hires https://www.oncohost.com/news/health-it-appointments-and-hires-2 https://www.oncohost.com/news/health-it-business-news https://www.oncohost.com/news/health-it-business-news---january-23-2025 https://www.oncohost.com/news/health-it-business-news-february-9-2023 https://www.oncohost.com/news/health-it-business-news-financial-edition-october-19-2023 https://www.oncohost.com/news/health-it-business-news-january-12-2023 https://www.oncohost.com/news/health-it-business-news-june-16-2022 https://www.oncohost.com/news/health-it-business-news-november-17-2022 https://www.oncohost.com/news/health-it-business-news-nurses-week-special-edition-may-11-2023 https://www.oncohost.com/news/health-it-hires-appointments-and-whos-hiring https://www.oncohost.com/news/health-it-product-news-report-february-2023 https://www.oncohost.com/news/health-tech-world-awards-recognising-the-most-impactful-startups https://www.oncohost.com/news/henlius-and-oncohost-partner-to-predict-trial-outcomes-using-machine-learning https://www.oncohost.com/news/hillels-tech-corner-cancer-treatment-personalized https://www.oncohost.com/news/how-an-ai-tool-predicts-responses-to-cancer-treatment https://www.oncohost.com/news/immunotherapy-month-and-much-more https://www.oncohost.com/news/in-brief-this-week https://www.oncohost.com/news/in-brief-this-week-qiagen-renalytix-opgen-perkinelmer-avacta-paige-more https://www.oncohost.com/news/is-chatgpt-fast-becoming-chatmd-introducing-generative-ai-to-healthcare https://www.oncohost.com/news/israel-based-oncohost-closes-8m-in-series-b-funding-to-provide-personalized-cancer-therapy-for-more-effective-treatment https://www.oncohost.com/news/israel-is-starting-to-win-the-battle-with-cancer https://www.oncohost.com/news/israel-oncohost-wins-gold-at-the-2025-merit-awards-for-cancer-research-companies https://www.oncohost.com/news/israeli-algorithm-may-predict-if-cancer-patients-will-respond-to-treatment https://www.oncohost.com/news/israeli-biotech-startup-oncohost-raises-35-million-in-funding-to-personalize-cancer-treatment-using-ai https://www.oncohost.com/news/israeli-blood-test-offers-better-choices-to-fight-cancer https://www.oncohost.com/news/israeli-med-tech-companies-adapt-to-wartime-footing https://www.oncohost.com/news/israeli-research-institute-makes-great-contributions-to-cancer-research https://www.oncohost.com/news/israeli-startup-founders-go-to-war-were-fighting-for-our-home https://www.oncohost.com/news/israeli-startup-oncohost-eyeing-2022-commercial-launch-of-immunotherapy-response-prediction-test https://www.oncohost.com/news/israeli-startup-oncohost-raises-8m-for-ai-precision-oncology-platform https://www.oncohost.com/news/israeli-startup-oncohost-wins-global-award-for-proteomics-innovation https://www.oncohost.com/news/israeli-startup-to-showcase-ai-cancer-tool-at-top-oncology-summit https://www.oncohost.com/news/israeli-startups-eye-growing-precision-oncology-market https://www.oncohost.com/news/israeli-technique-predicts-patient-response-to-immunotherapy https://www.oncohost.com/news/israels-oncohost-uks-nhs-to-study-cancer-patient-responses-to-immunotherapies https://www.oncohost.com/news/israels-oncohost-wins-2025-precision-oncology-award-for-ai-based-cancer-treatment https://www.oncohost.com/news/january-2021-smiles-upon-israeli-startups-4-new-unicorns-and-over-1b-in-funding https://www.oncohost.com/news/jitc-publishes-oncohost-study-identifying-predictive-proteomic-signature-to-analyze-treatment-resistance-in-nsclc-patients https://www.oncohost.com/news/leading-cancer-institute-dana-farber-to-partner-with-oncohost-for-groundbreaking-cancer-study https://www.oncohost.com/news/lifting-the-veil-of-uncertainty-around-cancer-treatments https://www.oncohost.com/news/matching-patients-with-treatments-developing-clinically-meaningful-diagnostics-to-inform-cancer-immunotherapy-selection https://www.oncohost.com/news/may-10-quick-takes-molecular-machines-company-moma-lands-150m-series-b https://www.oncohost.com/news/money-on-the-move-january-15-20 https://www.oncohost.com/news/new-cancer-research-for-personalized-care https://www.oncohost.com/news/new-clinical-study-identifies-personalized-treatment-options-for-metastatic-nsclc-with-plasma-proteome-testing https://www.oncohost.com/news/new-directions-what-innovations-are-coming-down-the-pike-for-lung-cancer https://www.oncohost.com/news/new-israeli-technology-improves-prediction-of-patient-response-to-immunotherapy https://www.oncohost.com/news/new-israeli-technology-improves-prediction-of-patient-response-to-immunotherapy-2 https://www.oncohost.com/news/new-study-combines-ai-and-multiomics-analysis-to-understand-cancer-resistance-mechanisms https://www.oncohost.com/news/new-test-influences-first-line-therapy-decisions-for-metastatic-nsclc-patients https://www.oncohost.com/news/next-israeli-astronauts-35-experiments-revealed https://www.oncohost.com/news/ngs-solution-detects-aneuploidies-ai-powered-biomarker-test-for-urothelial-cancer https://www.oncohost.com/news/nhs-opens-8-clinical-trial-sites-to-assess-cancer-treatment https://www.oncohost.com/news/nhs-opens-eight-uk-clinical-trial-sites-to-assess-cancer-patient-response-to-immunotherapy-in-collaboration-with-oncohost https://www.oncohost.com/news/nhs-opens-eight-uk-clinical-trial-sites-to-assess-cancer-patient-response-to-immunotherapy-in-collaboration-with-oncohost-2 https://www.oncohost.com/news/ninety-three-percent-of-oncologists-adjust-treatment-recommendations-with-oncohosts-prophetnsclc-test https://www.oncohost.com/news/nobel-laureate-prof-aaron-ciechanover-to-discuss-advances-in-precision-medicine https://www.oncohost.com/news/nobel-prizewinner-ciechanover-hails-much-more-precise-cancer-treatment https://www.oncohost.com/news/novel-diagnostic-platform-predicts-nsclc-patient-response-to-immunotherapy https://www.oncohost.com/news/observational-study-demonstrates-clinical-validity-and-utility-of-oncohosts-prophet-nsclc-test https://www.oncohost.com/news/oncohost-accepted-to-present-poster-at-esmo-2024 https://www.oncohost.com/news/oncohost-advances-plasma-proteomics-for-nsclc-immunotherapy-monitoring-and-prediction https://www.oncohost.com/news/oncohost-and-dana-farber-partner-on-kidney-cancer-rcc-biomarker-study https://www.oncohost.com/news/oncohost-announced-official-launch-of-prophet-non-small-cell-lung-cancer-nsclc-test-in-the-united-states https://www.oncohost.com/news/oncohost-announces-ai-based-clinical-trial-collaboration-to-analyze-immunotherapy-resistance https://www.oncohost.com/news/oncohost-announces-executive-appointment-of-ron-andrews https://www.oncohost.com/news/oncohost-announces-interim-results-from-prophetic-trial-multicenter-assessment-of-nsclc-patient-response-to-immunotherapy https://www.oncohost.com/news/oncohost-announces-new-study-on-biomarkers-for-renal-cell-carcinoma https://www.oncohost.com/news/oncohost-announces-three-abstracts-selected-for-presentation-at-wclc-2024 https://www.oncohost.com/news/oncohost-awarded-best-practices-technology-innovation-leadership-award-in-the-ai-based-precision-oncology-industry-by-frost-sullivan https://www.oncohost.com/news/oncohost-awarded-eu2-5m-grant-from-the-eic-transition-programme-to-advance-precision-oncology https://www.oncohost.com/news/oncohost-bgn-technologies-sign-option-agreement https://www.oncohost.com/news/oncohost-breakthrough-enables-integration-of-serum-and-plasma-proteomic-data-for-enhanced-cancer-biomarker-research https://www.oncohost.com/news/oncohost-celebrates-big-innovation-award-in-precision-oncology https://www.oncohost.com/news/oncohost-chris-dingman-james-whelan https://www.oncohost.com/news/oncohost-collaborates-with-lung-biobank-heidelberg-to-discover-lung-cancer-biomarkers https://www.oncohost.com/news/oncohost-data-on-host-immunotherapy-response-to-be-presented-this-week https://www.oncohost.com/news/oncohost-david-gandara https://www.oncohost.com/news/oncohost-developing-neutroflow-test-for-guiding-cancer-therapy-selection https://www.oncohost.com/news/oncohost-develops-predictive-biomarker-for-immune-related-adverse-events-in-nsclc-patients https://www.oncohost.com/news/oncohost-earns-cap-accreditation-for-cary-laboratory https://www.oncohost.com/news/oncohost-enters-trial-partnership-to-evaluate-resistance-to-immunotherapy https://www.oncohost.com/news/oncohost-finding-new-better-immunotherapies-for-complex-cancers https://www.oncohost.com/news/oncohost-further-assessing-protein-signature-for-predicting-nsclc-patients-immunotherapy-response https://www.oncohost.com/news/oncohost-gains-new-york-state-laboratory-permit-for-prophetnsclc-test https://www.oncohost.com/news/oncohost-granted-new-york-state-lab-permit-enabling-prophetnsclc-r-nationwide-access https://www.oncohost.com/news/oncohost-guiding-oncology-treatment-decisions-with-one-blood-draw https://www.oncohost.com/news/oncohost-heidelberg-university-hospital-strike-lung-cancer-biomarker-alliance https://www.oncohost.com/news/oncohost-hengenix-biotech-exploring-lung-cancer-resistance-biomarkers-in-immunotherapy-trial https://www.oncohost.com/news/oncohost-hires-ron-andrews-as-strategic-consultant-to-the-ceo https://www.oncohost.com/news/oncohost-hospital-partners-nab-eu2-5m-grant-for-cancer-treatment-biomarker-development https://www.oncohost.com/news/oncohost-hospital-partners-nab-eu2-5m-grant-for-cancer-treatment-biomarker-development-2 https://www.oncohost.com/news/oncohost-launches-non-small-cell-lung-cancer-test-in-u-s https://www.oncohost.com/news/oncohost-launches-nsclc-test-in-the-u-s https://www.oncohost.com/news/oncohost-launches-nsclc-test-in-the-united-states https://www.oncohost.com/news/oncohost-launches-prophet-nsclc-cancer-test-in-the-united-states https://www.oncohost.com/news/oncohost-launches-prophet-r-nsclc-cancer-test-in-the-united-states https://www.oncohost.com/news/oncohost-launches-prophet-r-nsclc-test-in-the-united-states https://www.oncohost.com/news/oncohost-launches-study-on-biomarkers-for-renal-cell-carcinoma https://www.oncohost.com/news/oncohost-licenses-biosensing-technology-from-bgn-technologies-to-predict-immunotherapy-response https://www.oncohost.com/news/oncohost-licenses-somalogic-platform-to-develop-tests-to-predict-patient-response-to-immunotherapies https://www.oncohost.com/news/oncohost-nabs-35m-in-funding-round https://www.oncohost.com/news/oncohost-nabs-8m-series-b-round-for-ai-powered-precision-oncology-platform https://www.oncohost.com/news/oncohost-named-gold-winner-in-2025-merit-awards https://www.oncohost.com/news/oncohost-named-gold-winner-in-2025-merit-awards-for-business-in-research-development https://www.oncohost.com/news/oncohost-named-gold-winner-in-2025-merit-awards-for-healthcare---technology-solution-of-the-year https://www.oncohost.com/news/oncohost-named-technology-solution-of-the-year-at-2025-merit-awards-for-healthcare https://www.oncohost.com/news/oncohost-named-top-precision-oncology-solution-for-2025 https://www.oncohost.com/news/oncohost-offers-new-hope-for-cancer-sufferers https://www.oncohost.com/news/oncohost-on-liquid-biopsy-ai-and-developing-israels-life-sciences-ecosystem https://www.oncohost.com/news/oncohost-opens-trial-sites-for-study-evaluating-its-ai-proteomics-profiling-technology https://www.oncohost.com/news/oncohost-partners-with-gustave-roussy-cancer-institute https://www.oncohost.com/news/oncohost-partners-with-gustave-roussy-cancer-institute-2 https://www.oncohost.com/news/oncohost-partners-with-gustave-roussy-cancer-institute-to-advance-predictive-markers-for-immune-related-adverse-events https://www.oncohost.com/news/oncohost-partners-with-gustave-roussy-cancer-institute-to-advance-predictive-markers-for-immune-related-adverse-events-2 https://www.oncohost.com/news/oncohost-partners-with-us-research-institutions-to-analyze-resistance-mechanisms-in-cancer https://www.oncohost.com/news/oncohost-personalized-cancer-therapy-for-more-effective-treatment https://www.oncohost.com/news/oncohost-personalizing-cancer-treatment-based-on-host-response https://www.oncohost.com/news/oncohost-platform-improves-immunotherapy-response-predictions https://www.oncohost.com/news/oncohost-platform-predicts-response-to-lung-cancer-therapy https://www.oncohost.com/news/oncohost-preparing-launch-of-proteomics-diagnostics-platform-for-cancer-immunotherapy https://www.oncohost.com/news/oncohost-proteomics-lab-earns-cap-accreditation https://www.oncohost.com/news/oncohost-publishes-landmark-jpba-proteomics-study https://www.oncohost.com/news/oncohost-publishes-landmark-study-in-jpba-demonstrating-serum-plasma-proteomic-bridging-expanding-biomarker-research-capabilities https://www.oncohost.com/news/oncohost-publishes-landmark-study-in-jpba-demonstrating-serum-plasma-proteomic-bridging-expanding-biomarker-research-capabilities-2 https://www.oncohost.com/news/oncohost-publishes-landmark-study-in-jpba-demonstrating-serum-plasma-proteomic-bridging-expanding-biomarker-research-capabilities-3 https://www.oncohost.com/news/oncohost-raises-35-million-series-c-funding-round-to-launch-blood-test-that-may-rewrite-the-standard-of-care-for-precision-oncology https://www.oncohost.com/news/oncohost-raises-35-million-series-c-funding-round-to-launch-blood-test-that-may-rewrite-the-standard-of-care-for-precision-oncology-2 https://www.oncohost.com/news/oncohost-raises-35m-for-ai-powered-precision-oncology-platform https://www.oncohost.com/news/oncohost-raises-35m-for-precision-oncology-diagnostic-solution https://www.oncohost.com/news/oncohost-raises-35m-in-series-c-financing https://www.oncohost.com/news/oncohost-raises-35m-in-series-c-funding https://www.oncohost.com/news/oncohost-raises-8-million-in-series-b-funding-round https://www.oncohost.com/news/oncohost-raises-8-million-to-develop-ai-that-predicts-cancer-treatment-responses https://www.oncohost.com/news/oncohost-raybiotech-awarded-1-million-grant-for-precision-oncology https://www.oncohost.com/news/oncohost-raybiotech-win-1m-from-bird-foundation https://www.oncohost.com/news/oncohost-receives-a-eu2-5-million-european-grant-to-advance-precision-oncology https://www.oncohost.com/news/oncohost-receives-lab-permit-from-new-york-state-doh https://www.oncohost.com/news/oncohost-receives-lab-permit-from-new-york-state-doh-2 https://www.oncohost.com/news/oncohost-receives-lab-permit-from-new-york-state-doh-3 https://www.oncohost.com/news/oncohost-receives-new-york-state-laboratory-permit-expanding-availability-of-prophetnsclc-r-precision-oncology-test https://www.oncohost.com/news/oncohost-receives-new-york-state-laboratory-permit-expanding-availability-of-prophetnsclc-r-precision-oncology-test-2 https://www.oncohost.com/news/oncohost-receives-new-york-state-laboratory-permit-for-precision-oncology-test https://www.oncohost.com/news/oncohost-secures-8-million-series-b-funding-round https://www.oncohost.com/news/oncohost-secures-8m-in-series-b-funding https://www.oncohost.com/news/oncohost-secures-new-york-state-laboratory-permit-expands-access-to-prophetnsclc-r-precision-oncology-test-across-the-u-s https://www.oncohost.com/news/oncohost-secures-usd-2-8m-grant-eic-transition-programme https://www.oncohost.com/news/oncohost-showcases-innovative-insights-in-nsclc-proteomics https://www.oncohost.com/news/oncohost-strengthens-leadership-with-ron-andrews-appointment https://www.oncohost.com/news/oncohost-study-offers-insights-into-resistance-mechanisms-in-immunotherapy-treated-lung-cancer https://www.oncohost.com/news/oncohost-study-offers-new-insights-into-resistance-mechanisms-in-immunotherapy-treated-lung-cancer-patients https://www.oncohost.com/news/oncohost-study-offers-new-insights-into-resistance-mechanisms-in-immunotherapy-treated-lung-cancer-patients-2 https://www.oncohost.com/news/oncohost-to-launch-prophet-for-non-small-cell-lung-cancer-in-the-u-s-in-2023 https://www.oncohost.com/news/oncohost-to-present-new-research-on-proteomic-aging-biomarkers-outcomes-at-aacr-2026 https://www.oncohost.com/news/oncohost-to-present-poster-demonstrating-prophet-r-s-application-in-multiple-cancer-indications-at-asco-2024 https://www.oncohost.com/news/oncohost-to-present-prophet-r-biomarker-model-that-accurately-predicts-clinical-benefit-to-ici-based-treatment https://www.oncohost.com/news/oncohost-to-present-proteomics-based-biomarker-model-for-clinical-benefit-to-immunotherapy-in-nsclc-patients-at-sitc-2022 https://www.oncohost.com/news/oncohost-to-present-proteomics-based-predictive-biomarker-for-immune-related-adverse-events-in-nsclc-patients https://www.oncohost.com/news/oncohost-to-present-proteomics-based-predictive-biomarker-for-immune-related-adverse-events-in-nsclc-patients-at-sitc-2023 https://www.oncohost.com/news/oncohost-to-present-two-posters-highlighting-advances-in-plasma-proteomics-monitoring-and-prediction-for-nsclc-at-islb-2025 https://www.oncohost.com/news/oncohost-unveils-breakthrough-in-serum-and-plasma-proteomic-data-integration https://www.oncohost.com/news/oncohost-wins-2023-big-innovation-award-for-prophet-r-platform https://www.oncohost.com/news/oncohost-wins-2025-big-innovation-award-for-healthcare https://www.oncohost.com/news/oncohost-wins-2025-big-innovation-award-for-healthcare-2 https://www.oncohost.com/news/oncohost-wins-2026-big-innovation-award-for-ai-driven-oncology-platform https://www.oncohost.com/news/oncohost-wins-ai-excellence-award https://www.oncohost.com/news/oncohost-wins-eu2-5m-grant-to-advance-precision-oncology https://www.oncohost.com/news/oncohost-wins-frost-sullivan-2021-technology-innovation-leadership-award-for-excellence-in-best-practices https://www.oncohost.com/news/oncohost-wins-gold-for-ai-powered-cancer-prediction-platform https://www.oncohost.com/news/oncohost-wins-gold-for-r-d-innovation-in-precision-oncology https://www.oncohost.com/news/oncohost-wins-proteomics-innovation-of-the-year-at-the-biotech-breakthrough-awards https://www.oncohost.com/news/oncohost-wins-proteomics-innovation-of-the-year-for-prophet-platform https://www.oncohost.com/news/oncohosts-35m-series-c-predicts-expansion-of-prophet-study https://www.oncohost.com/news/oncohosts-algorithms-predict-cancer-patients-response-to-treatments https://www.oncohost.com/news/oncohosts-ceo-is-prophet-ic-about-his-diagnostics-potential-to-transform-care https://www.oncohost.com/news/oncohosts-focus-on-the-patient-offers-precision-oncology-to-combat-cancer https://www.oncohost.com/news/oncology-molecular-diagnostics-market-set-to-hit-6-46b-by-2033-amid-ai-liquid-biopsy-surge https://www.oncohost.com/news/oncology-peer-review-on-the-go-ofer-sharon-md-discusses-oncohost-and-prophetic-trial-for-nsclc https://www.oncohost.com/news/other-news-to-note-for-may-15-2025 https://www.oncohost.com/news/other-news-to-note-for-oct-3-2023 https://www.oncohost.com/news/ourcrowd-leads-8m-series-b-in-israeli-personalized-cancer-therapy-startup https://www.oncohost.com/news/part-1-yuval-shaked-asco-2020-host-response-profiling-for-melanoma-patients https://www.oncohost.com/news/part-2-yuval-shaked-asco-2020-host-response-profiling-for-melanoma-patients https://www.oncohost.com/news/personalized-cancer-therapy-co-oncohost-raises-35m https://www.oncohost.com/news/personalized-cancer-treatment-a-real-possibility https://www.oncohost.com/news/pharma-2023-health-it-predictions https://www.oncohost.com/news/plasma-proteomic-profiling-as-a-precision-oncology-tool https://www.oncohost.com/news/podcast-proteomics-predictor-for-immunotherapy-benefit https://www.oncohost.com/news/precision-oncology-platform-oncohost-scores-35-million https://www.oncohost.com/news/predicting-immune-related-adverse-events-through-machine-learning-with-oncohost-dr-waqas-haque-dr-matthew-hadfield-and-dr-ofer-sharon https://www.oncohost.com/news/predicting-immunotherapy-success-via-biomarkers https://www.oncohost.com/news/prophet-biomarker-model-results-to-be-presented https://www.oncohost.com/news/prophet-platforms-predictive-ability-to-be-demonstrated https://www.oncohost.com/news/prophetic-study-of-immunotherapy-diagnostic-adds-new-site-in-buffalo-ny https://www.oncohost.com/news/proteins-provide-clue-to-predict-cancer-treatment-outcome https://www.oncohost.com/news/proteomics-and-prognostics-may-serve-as-potential-biomarkers-beyond-pd-l1-in-lung-cancer https://www.oncohost.com/news/singapore-delegation-meets-israeli-startups-in-tel-aviv https://www.oncohost.com/news/somalogic-announces-license-agreement-with-oncohost-for-the-development-of-precision-cancer-diagnostics https://www.oncohost.com/news/somalogic-in-licensing-deal-with-oncohost https://www.oncohost.com/news/somalogic-inks-license-deal-with-oncohost-to-develop-precision-cancer-diagnostics https://www.oncohost.com/news/somalogic-oncohost-announce-license-agreement-for-the-development-of-precision-cancer-diagnostics https://www.oncohost.com/news/somalogic-oncohost-ink-agreement-to-develop-tests https://www.oncohost.com/news/somalogic-oncohost-sign-agreement-to-develop-precision-cancer-therapy https://www.oncohost.com/news/somalogic-partners-with-oncohost-for-precision-cancer-diagnostics https://www.oncohost.com/news/space-meat-and-hummus-israel-finalizes-experiments-for-upcoming-iss-mission https://www.oncohost.com/news/startup-develops-blood-test-that-aims-to-undermine-tumors-resilience https://www.oncohost.com/news/study-demonstrates-clinical-validity-of-oncohosts-nsclc-test https://www.oncohost.com/news/study-in-jco-r-precision-oncology-validates-clinical-efficacy-of-oncohosts-prophet-r-nsclc-test https://www.oncohost.com/news/study-protein-indicates-likely-success-of-cancer-immunotherapy https://www.oncohost.com/news/surveys-and-reports-roundup https://www.oncohost.com/news/tech-transfer-roundup-md-anderson-moffitt-lead-busy-academic-cancer-partnering-space https://www.oncohost.com/news/texas-research-institute-tgen-oncohost-partner-to-id-lung-cancer-resistance-mechanisms https://www.oncohost.com/news/the-accelerating-state-of-ai-health-in-hospitals-and-homes https://www.oncohost.com/news/the-evolution-of-machine-learning-in-oncology-an-interview-with-dr-ofer-sharon https://www.oncohost.com/news/the-frontier-of-cancer-research https://www.oncohost.com/news/the-impact-of-proteomics-on-precision-oncology https://www.oncohost.com/news/the-impact-of-technology-on-healthcare https://www.oncohost.com/news/the-weekly-recap-2-28-25-lsi-alumni-achievements-driving-medtech-and-healthtech-forward https://www.oncohost.com/news/the-weekly-recap-5-16-25-lsi-alumni-achievements-driving-medtech-and-healthtech-forward https://www.oncohost.com/news/top-5-recent-advances-in-israeli-cancer-research-and-treatment https://www.oncohost.com/news/us-israel-foundation-to-invest-8m-in-9-new-joint-initiatives https://www.oncohost.com/news/weekly-quick-hits-research-triangle-park-week-of-october-23-2023 https://www.oncohost.com/news/whats-ahead-for-the-health-care-industry-in-2025 https://www.oncohost.com/news/which-israeli-technologies-will-soon-be-going-to-space https://www.oncohost.com/news/with-workers-called-to-battle-israeli-firms-rally-support https://www.oncohost.com/news/world-cancer-day-trends-in-cancer-therapeutics-to-look-forward-to-in-2025 https://www.oncohost.com/news/younger-people-are-getting-cancer-more-and-more-we-have-to-make-kinder-medicines https://www.oncohost.com/events/18th-annual-new-york-lung-cancers-symposium-r https://www.oncohost.com/events/18th-annual-personalized-medicine-conference https://www.oncohost.com/events/19th-annual-fall-midwest-thoracic-and-gi-oncology-conference https://www.oncohost.com/events/19th-annual-ny-lung-cancer-symposium https://www.oncohost.com/events/2023-flasco-fall-session https://www.oncohost.com/events/2023-iaslc-north-american-conference-of-lung-cancer https://www.oncohost.com/events/2023-sitc-38th-annual-meeting https://www.oncohost.com/events/2024-annual-breath-of-hope-ohio-gala https://www.oncohost.com/events/2024-annual-symposium-for-evolving-therapies-and-drug-development-in-oncology-inova https://www.oncohost.com/events/2024-flasco-fall-session https://www.oncohost.com/events/2024-masters-in-thoracic-oncology-summit https://www.oncohost.com/events/2024-sitc-39th-annual-meeting https://www.oncohost.com/events/2024-world-conference-on-lung-cancer-wclc https://www.oncohost.com/events/2025-cola-laboratory-enrichment-forum https://www.oncohost.com/events/2025-flasco-early-lung-cancer-summit https://www.oncohost.com/events/2025-healthcare-marketing-physician-strategies-summit https://www.oncohost.com/events/21st-annual-winter-lung-cancer-conference https://www.oncohost.com/events/22nd-annual-winter-lung-cancer-conference https://www.oncohost.com/events/25th-annual-international-lung-cancer-congress https://www.oncohost.com/events/2nd-annual-hawaii-lung-conference https://www.oncohost.com/events/3rd-annual-hawaii-lung-conference https://www.oncohost.com/events/42nd-annual-j-p-morgan-healthcare-conference https://www.oncohost.com/events/5th-annual-islb-congress-of-liquid-biopsy https://www.oncohost.com/events/aacr-2025 https://www.oncohost.com/events/aacr-annual-meeting-2023 https://www.oncohost.com/events/aacr-annual-meeting-2024 https://www.oncohost.com/events/ahci-best-of-asco-2024 https://www.oncohost.com/events/asco-2025 https://www.oncohost.com/events/asco-2026 https://www.oncohost.com/events/asco-annual-meeting-2023 https://www.oncohost.com/events/asco-annual-meeting-2024 https://www.oncohost.com/events/asco-gu---genitourinary-cancers-symposium https://www.oncohost.com/events/best-of-asco-miami https://www.oncohost.com/events/biomed-israel-2025 https://www.oncohost.com/events/community-oncology-forum https://www.oncohost.com/events/dc-lung-cancer-conference-2024 https://www.oncohost.com/events/duke-cancer-review https://www.oncohost.com/events/ecog-acrin-spring-2025-group-meeting https://www.oncohost.com/events/esmo-congress-2023 https://www.oncohost.com/events/esmo-congress-2024 https://www.oncohost.com/events/florida-cancer-specialists-clinical-summit-2024 https://www.oncohost.com/events/heartland-cancer-foundation-hcf-oncology-symposium https://www.oncohost.com/events/hlth-europe-2024 https://www.oncohost.com/events/iaslc-2024-targeted-therapies-of-lung-cancer-meeting https://www.oncohost.com/events/iaslc-2025-hot-topic-in-basic-and-translational-science-small-cell-lung-cancer-meeting https://www.oncohost.com/events/innovations-in-biopharma-2025 https://www.oncohost.com/events/international-lung-cancer-congress https://www.oncohost.com/events/io360-summit https://www.oncohost.com/events/islb-2024---6th-annual-congress-of-liquid-biopsy https://www.oncohost.com/events/join-our-ceo-at-lsi-europe-23-emerging-medtech-summit https://www.oncohost.com/events/join-us-at-best-of-lung-cancer-2023-conference-west-palm-beach https://www.oncohost.com/events/join-us-at-ilcc-2023-huntington-beach https://www.oncohost.com/events/join-us-at-the-bio-international-convention-2023 https://www.oncohost.com/events/masters-in-thoracic-oncology-summit-matos-2023 https://www.oncohost.com/events/medcity-invest-2024 https://www.oncohost.com/events/miami-cancer-institute-precision-oncology-symposium https://www.oncohost.com/events/moasc-annual-oncology-summit-research-symposium https://www.oncohost.com/events/nccn-2025 https://www.oncohost.com/events/nebraska-cancer-specialists-ncs-hope-foundation https://www.oncohost.com/events/nebraska-oncology-society https://www.oncohost.com/events/new-orleans-summer-cancer-meeting https://www.oncohost.com/events/new-york-lung-cancer-foundation-summit https://www.oncohost.com/events/noscm-20th-annual-new-orleans-summer-cancer-meeting https://www.oncohost.com/events/ny-lung-cancer-foundations-call-to-action-forum https://www.oncohost.com/events/precision-medicine-world-conference-pmwc-2024 https://www.oncohost.com/events/ttlc-2025 https://www.oncohost.com/events/ut-southwestern---2024-oncology-year-in-review https://www.oncohost.com/events/west-oncology-conference-2024 https://www.oncohost.com/open-positions/director-of-laboratory-operations https://www.oncohost.com/open-positions/head-of-data-science https://www.oncohost.com/open-positions/senior-marcom-associate---maternity-leave-cover https://www.oncohost.com/thought-leadership/a-multicomponent-biomarker-approach-will-shift-cancer-care https://www.oncohost.com/thought-leadership/a-new-approach-to-personalized-immunotherapy https://www.oncohost.com/thought-leadership/adopting-ai-in-biologics-discovery https://www.oncohost.com/thought-leadership/bringing-hope-to-patients-with-stage-iv-non-small-cell-lung-cancer https://www.oncohost.com/thought-leadership/cancer-therapy-in-2020-the-promise-of-host-response-profiling https://www.oncohost.com/thought-leadership/collaboration-is-the-key-to-advancing-cancer-care https://www.oncohost.com/thought-leadership/composite-intelligence-how-ai-driven-biomarkers-are-setting-the-bar-in-immuno-oncology https://www.oncohost.com/thought-leadership/from-standardized-to-specialized-revolutionizing-lung-cancer-care https://www.oncohost.com/thought-leadership/how-can-we-investigate-biomarkers-for-lung-cancer-patients-more-effectively https://www.oncohost.com/thought-leadership/oncohost-developing-neutroflow-test-for-guiding-cancer-therapy-selection https://www.oncohost.com/thought-leadership/revealing-the-blind-spot-in-cancer-treatment-with-host-response-profiling https://www.oncohost.com/thought-leadership/the-crucial-role-of-artificial-intelligence-in-enhancing-clinical-outcomes https://www.oncohost.com/thought-leadership/the-next-frontier-in-immunotherapy-predicting-and-preventing-immune-related-adverse-events https://www.oncohost.com/thought-leadership/this-time-its-personal https://www.oncohost.com/thought-leadership/transforming-healthcare-with-ai-navigating-the-future-of-medicine https://www.oncohost.com/thought-leadership/treating-cancer-with-precision-its-time-for-host-response-profiling https://www.oncohost.com/thought-leadership/unlocking-the-potential-of-ai-driven-biomarkers-a-new-era-in-personalized-cancer-care https://www.oncohost.com/press-releases/baylor-scott-white-research-institute-tgen-and-oncohost-announce-new-research-study-to-analyze-resistance-mechanisms-in-lung-cancer https://www.oncohost.com/press-releases/bird-israel-u-s-binational-industrial-r-d-foundation-to-invest-8-million-in-9-new-projects https://www.oncohost.com/press-releases/clinical-lung-cancer-publishes-study-93-of-oncologists-adjust-treatment-recommendations-with-oncohosts-prophetnsclc-tm-test https://www.oncohost.com/press-releases/jco-r-precision-oncology-jco-po-publishes-study-demonstrating-clinical-validity-and-utility-of-oncohosts-prophet-r-nsclc-test https://www.oncohost.com/press-releases/jitc-publishes-oncohost-study-identifying-predictive-proteomic-signature-to-analyze-treatment-resistance-in-nsclc-patients https://www.oncohost.com/press-releases/journal-of-pharmaceutical-biomedical-analysis-publishes-study-analytically-validating-oncohosts-prophet-r-test-as-a-decision-support-tool-for-metastatic-nsclc-patients https://www.oncohost.com/press-releases/nhs-opens-eight-uk-clinical-trial-sites-to-assess-cancer-patient-response-to-immunotherapy-in-collaboration-with-oncohost https://www.oncohost.com/press-releases/oncohost-accepted-to-present-poster-demonstrating-prophet-r-s-application-in-renal-cell-carcinoma-at-esmo-2024 https://www.oncohost.com/press-releases/oncohost-and-raybiotech-awarded-1-million-grant-from-the-bird-foundation-to-advance-precision-oncology-for-patients-receiving-immunotherapy https://www.oncohost.com/press-releases/oncohost-announces-clinical-trial-collaboration-with-roswell-park-comprehensive-cancer-center-to-analyze-immunotherapy-resistance https://www.oncohost.com/press-releases/oncohost-announces-collaboration-with-heidelberg-universitys-lung-research-biobank-to-discover-lung-cancer-biomarkers https://www.oncohost.com/press-releases/oncohost-announces-executive-appointment-of-ron-andrews https://www.oncohost.com/press-releases/oncohost-announces-interim-results-from-prophetic-trial-multicenter-assessment-of-nsclc-patient-response-to-immunotherapy https://www.oncohost.com/press-releases/oncohost-announces-new-executive-appointments-ahead-of-imminent-launch-of-its-precision-oncology-platform https://www.oncohost.com/press-releases/oncohost-announces-new-study-on-biomarkers-for-renal-cell-carcinoma https://www.oncohost.com/press-releases/oncohost-announces-three-abstracts-accepted-for-presentation-at-asco-2025 https://www.oncohost.com/press-releases/oncohost-announces-three-abstracts-selected-for-presentation-at-wclc-2024 https://www.oncohost.com/press-releases/oncohost-awarded-eu2-5-million-grant-from-the-eic-transition-programme-to-advance-precision-oncology-for-patients-receiving-immunotherapy https://www.oncohost.com/press-releases/oncohost-ceo-to-present-at-2022-bio-ceo-investor-conference https://www.oncohost.com/press-releases/oncohost-collaborates-with-bgn-technologies-to-predict-cancer-patient-response-to-anti-pd-1-treatment-with-icar-biosensing-tech https://www.oncohost.com/press-releases/oncohost-earns-cap-accreditation-for-cary-laboratory-highlighting-commitment-to-excellence-in-proteomic-based-diagnostics https://www.oncohost.com/press-releases/oncohost-highlights-advances-in-proteomic-research-with-abstracts-presented-at-islb-2024-6th-annual-congress-of-liquid-biopsy https://www.oncohost.com/press-releases/oncohost-launches-prophet-r-nsclc-test-in-the-united-states https://www.oncohost.com/press-releases/oncohost-named-gold-winner-in-2025-merit-awards-for-business-in-research-development https://www.oncohost.com/press-releases/oncohost-named-gold-winner-in-2025-merit-awards-for-healthcare---technology-solution-of-the-year https://www.oncohost.com/press-releases/oncohost-named-top-precision-oncology-solution-for-2025 https://www.oncohost.com/press-releases/oncohost-nature-reviews-cancer-article-outlines-host-response-analysis-as-new-tool-for-precision-medicine-in-oncology https://www.oncohost.com/press-releases/oncohost-opens-first-of-its-kind-proteomics-laboratory-for-host-response-analysis-for-cancer-therapy https://www.oncohost.com/press-releases/oncohost-partners-with-gustave-roussy-cancer-institute-to-advance-predictive-markers-for-immune-related-adverse-events https://www.oncohost.com/press-releases/oncohost-publishes-data-identifying-predictive-signature-for-response-to-immunotherapy-in-lung-cancer-patients https://www.oncohost.com/press-releases/oncohost-publishes-landmark-study-in-jpba-demonstrating-serum-plasma-proteomic-bridging-expanding-biomarker-research-capabilities https://www.oncohost.com/press-releases/oncohost-raises-35-million-series-c-funding-round-to-launch-blood-test-that-may-rewrite-the-standard-of-care-for-precision-oncology https://www.oncohost.com/press-releases/oncohost-receives-new-york-state-laboratory-permit-expanding-availability-of-prophetnsclc-r-precision-oncology-test https://www.oncohost.com/press-releases/oncohost-secures-8-million-series-b-funding-round-to-advance-its-ai-powered-precision-oncology-platform https://www.oncohost.com/press-releases/oncohost-selected-to-present-in-oral-minisymposium-at-american-association-of-cancer-research-aacr-annual-meeting-2024 https://www.oncohost.com/press-releases/oncohost-study-offers-new-insights-into-resistance-mechanisms-in-immunotherapy-treated-lung-cancer-patients https://www.oncohost.com/press-releases/oncohost-to-present-data-at-sitc-2021-on-predicting-nsclc-patient-response-to-immunotherapy-utilizing-proteomic-profiling https://www.oncohost.com/press-releases/oncohost-to-present-data-on-host-response-profiling-for-melanoma-patients-at-2020-asco-annual-meeting https://www.oncohost.com/press-releases/oncohost-to-present-data-on-host-response-profiling-for-nsclc-patients-at-esmo-virtual-congress-2020 https://www.oncohost.com/press-releases/oncohost-to-present-data-on-predicting-host-response-to-immunotherapy-at-the-map-2020-virtual-congress-esmo https://www.oncohost.com/press-releases/oncohost-to-present-data-on-predicting-host-response-to-immunotherapy-in-melanoma-patients-at-sitc-2020 https://www.oncohost.com/press-releases/oncohost-to-present-new-research-on-plasma-proteomics-based-treatment-selection-in-melanoma-at-esmo-2025 https://www.oncohost.com/press-releases/oncohost-to-present-new-research-on-proteomic-aging-biomarkers-outcomes-at-aacr-2026 https://www.oncohost.com/press-releases/oncohost-to-present-new-research-on-small-cell-lung-cancer-subtypes-at-wclc-2025 https://www.oncohost.com/press-releases/oncohost-to-present-poster-demonstrating-prophet-r-s-application-in-multiple-cancer-indications-at-asco-2024 https://www.oncohost.com/press-releases/oncohost-to-present-prophet-r-biomarker-model-that-accurately-predicts-clinical-benefit-to-ici-based-treatment-at-asco-2023 https://www.oncohost.com/press-releases/oncohost-to-present-proteomics-based-biomarker-model-for-clinical-benefit-to-immunotherapy-in-nsclc-patients-at-sitc-2022 https://www.oncohost.com/press-releases/oncohost-to-present-proteomics-based-predictive-biomarker-for-immune-related-adverse-events-in-nsclc-patients-at-sitc-2023 https://www.oncohost.com/press-releases/oncohost-to-present-two-posters-highlighting-advances-in-plasma-proteomics-monitoring-and-prediction-for-nsclc-at-islb-2025 https://www.oncohost.com/press-releases/oncohost-to-showcase-plasma-proteomics-research-in-nsclc-at-aacr-2025 https://www.oncohost.com/press-releases/oncohost-welcomes-nobel-prize-winner-to-scientific-advisory-board https://www.oncohost.com/press-releases/oncohost-welcomes-uc-davis-professor-david-gandara-m-d-to-scientific-advisory-board https://www.oncohost.com/press-releases/oncohost-wins-2023-big-innovation-award-for-prophet-r-platform https://www.oncohost.com/press-releases/oncohost-wins-2024-artificial-intelligence-excellence-award https://www.oncohost.com/press-releases/oncohost-wins-2025-big-innovation-award-for-healthcare https://www.oncohost.com/press-releases/oncohost-wins-2026-artificial-intelligence-excellence-award-in-health-category https://www.oncohost.com/press-releases/oncohost-wins-2026-big-innovation-award-in-health-category-named-a-top-10-innovator---small-business https://www.oncohost.com/press-releases/oncohost-wins-frost-sullivan-2021-technology-innovation-leadership-award-for-excellence-in-best-practices https://www.oncohost.com/press-releases/oncohost-wins-proteomics-innovation-of-the-year-at-the-biotech-breakthrough-awards https://www.oncohost.com/press-releases/oncohosts-prophet-r-platform-to-support-henlius-us-based-phase-iii-trial-for-patients-with-extensive-stage-small-cell-lung-cancer https://www.oncohost.com/press-releases/somalogic-announces-license-agreement-with-oncohost-for-the-development-of-precision-cancer-diagnostics